Homologus PRP in the Infiltrative Treatment of Knee Osteoarthritis in Young Athletic Patients
Istituto Ortopedico Rizzoli
30 participants
Oct 10, 2023
INTERVENTIONAL
Conditions
Summary
The study consists of 3 phases (enrollment, infiltrative procedure, and controls): * Identification by specialized orthopedic medical staff belonging to the SC Orthopedic and Trauma Clinic II of the Rizzoli Orthopedic Institute of subjects who meet the study inclusion criteria. Signing of informed consent form and completion of evaluation questionnaires. * infiltrative procedure * Patients will be clinically evaluated before the infiltration procedure and at 1, 3, 6, and 12 months after treatment by trained medical personnel (outcome assessors). Questionnaires will be administered for clinical evaluations before treatment and at these clinical checkups during follow-up. Any adverse events to treatment will also be assessed during follow-up visits. The duration and extent of joint swelling and pain following infiltration will be reported, and any drug therapies taken by the patient will be recorded.
Eligibility
Inclusion Criteria8
- Patients, both sexes, with symptomatic knee osteoarthritis with:
- Age: 18-40 years;
- Unilateral involvement;
- Signs and symptoms of knee osteoarthritis;
- Radiographic or MRI signs of degenerative pathology of knee cartilage (Kellgren-Lawrence grade 1-3);
- Ability and consent of patients to actively participate in clinical follow-up;
- Signature of informed consent;
- Pain ≥ 4 on VAS s
Exclusion Criteria10
- Patients unable to express consent;
- Patients undergoing intra-articular infiltration of other substance in the previous 6 months;
- Patients undergoing knee surgery in the previous 12 months;
- Patients with malignant neoplasms;
- Patients with rheumatic diseases;
- Patients with uncontrolled metabolic diseases;
- Patients with hematological diseases (coagulopathies);
- Patients abusing alcoholic beverages, drugs or medications;
- Knee trauma treated in the previous 6 months.
- Other conditions that may interfere with the evaluation of OA treatment.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
a single intra-articular infiltration of 5 mL of PRP-O will be performed by the infiltrating physician. It is specified that the PRP-O used within the study will be produced following the guidelines and standards for the production of blood products for non-transfusion use as already in place at the Unified Metropolitan Transfusion Service IOR site. PRP (Platelet Rich Plasma) is produced from platelet pool from donor buffy coat. PRP contains 1,000,000 PLT/mml +/- 20%, as required by current regulations.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06483269